Health Condition 1: J453- Mild persistent asthma Health Condition 2: null- Tamaka Shwasa
Conditions
Interventions
Intervention1: Ashtangavaleha prepared with classical method will be administered at a dose of 10 g twice daily orally for 28 days with luke warm water: AFI part II
Control Intervention1: Ashtangavale
Sponsors
Institute for Post Graduate Teaching and Research in Ayurveda
Eligibility
Inclusion criteria
Inclusion criteria: Both the sexes having age between 16 years to 60 years Mild persistent cases of Bronchial Asthma with daytime symptoms 3-6/week and nocturnal symptoms with 3-4/month Moderate persistence cases with daytime symptoms daily and nocturnal symptoms with one or more than one week but not more than 2 week
Exclusion criteria
Exclusion criteria: Known patients of diabetes Dyspnoea resulting from cardiac origin and anaemia Age above 60 years and below 16 years Patients suffering from tuberculosis, malignancy and other chronic debilitating diseases, HIV positive cases Pregnant and lactating mothers Patients who depend on regular use of inhalers Patients suffering with other types of Shwasa, i.e. Maha, Urdha, Chhinna Shwasa
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| It is expected that the trial drugs will exert a significant action on Signs and Symptoms of Tamaka Shwasa. Improvement in AEC and other haematological (TLC, DLC, Hb, AEC), Peak Expiratory Flow Rate and Breath Holding Time.Timepoint: Improvement in signs and symptoms, BHT and PEFR will be assessed before and after treatment (28 days of drug administration) | — |
Secondary
| Measure | Time frame |
|---|---|
| By providing better effect on Tamaka Shwasa, the drug will effect psychosomatic level of the enrolled patients, enhance quality of life and will contribute in reducing disability adjusted life years. Overall improvement in the disease condition, Quality of Life of the diseased. Based on the observations, the trial drug may be recommended to be added into the Essential Drugs List of Ministry of AYUSH, New DelhiTimepoint: 18 Months of Trial | — |
Countries
India
Contacts
Public ContactDr Galib
IPGT and RA
Outcome results
None listed